The prevention and management of stroke in sickle cell anaemia

Expert Opinion on Biological Therapy

Volumn 6, Issue 11, 2006, Pages 1087-1098

  Qureshi, N ^b   Lubin, B ^b   Walters, M C ^a  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

Haematopoietic cell transplantation; Hydroxyurea; Sickle cell disease; Stroke; Transfusion

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; DEFEROXAMINE; DIPYRIDAMOLE; HEPARIN; HYDROXYUREA; WARFARIN;

BRAIN DAMAGE; CELL TRANSPLANTATION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOPPLER ECHOGRAPHY; ERYTHROCYTE TRANSFUSION; HEMATOPOIETIC CELL; HUMAN; IRON OVERLOAD; LABORATORY TEST; PERIPHERAL OCCLUSIVE ARTERY DISEASE; REVIEW; RISK ASSESSMENT; SCREENING TEST; SICKLE CELL ANEMIA; STROKE; UNSPECIFIED SIDE EFFECT;

ANEMIA, SICKLE CELL; CEREBROVASCULAR ACCIDENT; DISEASE MANAGEMENT; HUMANS;

EID: 33750813283     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.6.11.1087     Document Type: Review

References (108)

1. CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC): Mortality among children with sickle cell disease identified by newborn screening during 1990-1994-California, Illinois, and New York. MMWR Morb. Mortal. Wkly Rep. (1998) 47(9):169-172.
2. MILLER ST, SLEEPER LA, PEGELOW CH et al.: Prediction of adverse outcomes in children with sickle cell disease. N. Engl. J. Med. (2000) 342(2):83-89. Analysis from the CSSCD that evaluated a newborn cohort with SCD for risk factors that might indicate early mortality and severe disease.
3. PLATT OS, BRAMBILLA DJ, ROSSE WF et al.: Mortality in sickle cell disease. Life expectancy and risk factors for early death. N. Engl. J. Med. (1994) 330(23):1639-1644.
4. REED W, VICHINSKY EP: Transfusion therapy: a coming-of-age treatment for patients with sickle cell disease. J. Pediatr. Hematol. Oncol. (2001) 23(4):197-202.
5. CHARACHE S, TERRIN ML, MOORE RD et al.: Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N. Engl. J. Med. (1995) 332(20):1317-1322.
6. STEINBERG MH: Management of sickle cell disease. N. Engl. J. Med. (1999) 340(13):1021-1030.
7. REED W, VICHINSKY EP: New considerations in the treatment of sickle cell disease. Annu. Rev. Med. (1998) 49:461-474.
8. FERSTER A, TAHRIRI P, VERMYLEN C et al.: Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood (2001) 97(11):3628-3632.
9. FERSTER A, DE VALCK C, AZZIN et al.: Bone marrow transplantation for severe sickle cell anaemia. Br. J. Haematol. (1992) 80(1):102-105. Early report that demonstrated the curative potential of HCT for SCD.
10. NAGEL RL: Severity, pathobiology, epistatic effects, and genetic markers in sickle cell anemia. Semin. Hematol. (1991) 28(3):180-201.
11. FIXLER J, STYLES L: Sickle cell disease. Pediatr. Clin. North Am. (2002) 49(6):1193-1210, vi.
12. NAGEL RL: Pleiotropic and epistatic effects in sickle cell anemia. Curr. Opin. Hematol. (2001) 8(2):105-110.
13. POWARS D, HITI A: Sickle cell anemia. Beta s gene cluster haplotypes as genetic markers for severe disease expression. Am. J. Dis. Child. (1993) 147(11):1197-1202.
14. OHENE-FREMPONG K, WEINER SJ, SLEEPER LA et al.: Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood (1998) 91(1):288-294. Report from the CSSCD that outlined the natural history of stroke in children and adults with SCD.
15. GASTON M, SMITH J, GALLAGHER D et al.: Recruitment in the Cooperative Study of Sickle Cell Disease (CSSCD). Control. Clin. Trials (1987) 8(4 Suppl.):131S-140S.
16. PEGELOW CH, MACKLIN EA, MOSER FG et al.: Longitudinal changes in brain magnetic resonance imaging findings in children with sickle cell disease. Blood (2002) 99(8):3014-3018.
17. STEEN RG, EMUDIANUGHE T, HANKINS GM et al.: Brain imaging findings in pediatric patients with sickle cell disease. Radiology (2003) 228(1):216-225.
18. MILLER ST, MACKLIN EA, PEGELOW CH et al.: Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: a report from the Cooperative Study of Sickle Cell Disease. J. Pediatr. (2001) 139(3):385-390. CSSCD report that identified the detection of silent cerebral infarction by MRI as a risk factor for stroke.
19. HOPPE C: Defining stroke risk in children with sickle cell anaemia. Br. J. Haematol. (2005) 128(6):751-766.
20. KINNEY TR, SLEEPER LA, WANG WC et al.: Silent cerebral infarcts in sickle cell anemia: a risk factor analysis. The Cooperative Study of Sickle Cell Disease. Pediatrics (1999) 103(3):640-645.
21. BALKARAN B, CHAR G, MORRIS JS et al.: Stroke in a cohort of patients with homozygous sickle cell disease. J. Pediatr. (1992) 120(3):360-366.
22. SHARMA P: Genes for ischaemic stroke: strategies for their detection. J. Hypertens. (1996) 14(3):277-285.
23. DRISCOLL MC, HURLET A, STYLES L et al.: Stroke risk in siblings with sickle cell anemia. Blood (2003) 101(6):2401-2404.
24. POWARS DR: Beta s-gene-cluster haplotypes in sickle cell anemia. Clinical and hematologic features. Hematol. Oncol. Clin. North Am. (1991) 5(3):475-493.
25. SARNAIK SA, BALLAS SK: Molecular characteristics of pediatric patients with sickle cell anemia and stroke. Am. J. Hematol. (2001) 67(3):179-182.
26. STEINBERG MH: Predicting clinical severity in sickle cell anaemia. Br. J. Haematol. (2005) 129(4):465-481.
27. HSU LL, MILLER ST, WRIGHT E et al.: Alpha Thalassemia is associated with decreased risk of abnormal transcranial Doppler ultrasonography in children with sickle cell anemia. J. Pediatr. Hematol. Oncol. (2003) 25(8):622-628.
28. NEONATO MG, GUILLOUD-BATAILLE M, BEAUVAIS P et al.: Acute clinical events in 299 homozygous sickle cell patients living in France. French Study Group on Sickle Cell Disease. Eur. J. Haematol. (2000) 65(3):155-164.
29. ADAMS RJ, KUTLAR A, MCKIE V et al.: Alpha thalassemia and stroke risk in sickle cell anemia. Am. J. Hematol. (1994) 45(4):279-282.
30. MILLER ST, RIEDER RF, RAO SP, BROWN AK: Cerebrovascular accidents in children with sickle-cell disease and alpha-thalassemia. J. Pediatr. (1988) 113(5):847-849.
31. WICK G, SCHETT G, AMBERGER A, KLEINDIENST R, XU Q: Is atherosclerosis an immunologically mediated disease? Immunol. Today (1995) 16(1):27-33.
32. DAHLEN GH, SLUNGA L, LINDBLOM B: Importance of Lp(a) lipoprotein and HLA genotypes in atherosclerosis and diabetes. Clin. Genet. (1994) 46(1 Spec. No.):46-51.
33. INOUE TK, IKEZAKI K, SASAZUKI T, MATSUSHIMA T, FUKUI M: Analysis of class II genes of human leukocyte antigen in patients with moyamoya disease. Clin. Neurol. Neurosurg. (1997) 99(Suppl. 2):S234-S237.
34. HOPPE C, KLITZ W, NOBLE J et al.: Distinct HLA associations by stroke subtype in children with sickle cell anemia. Blood (2003) 101(7):2865-2869.
35. BELCHER JD, MARKER PH, WEBER JP, HEBBEL RP, VERCELLOTTI GM: Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. Blood (2000) 96(7):2451-2459.
36. SHIU YT, UDDEN MM, MCINTIRE LV: Perfusion with sickle erythrocytes up-regulates ICAM-1 and VCAM-1 gene expression in cultured human endothelial cells. Blood (2000) 95(10):3232-3241.
37. GEE BE, PLATT OS: Sickle reticulocytes adhere to VCAM-1. Blood (1995) 85(1):268-274.
38. HOPPE C, KLITZ W, CHENG S et al.: Gene interactions and stroke risk in children with sickle cell anemia. Blood (2004) 103(6):2391-2396. Candidate genes associated with stroke are identified in this retrospective analysis.
39. TAYLOR JG, TANG DC, SAVAGE SA et al.: Variants in the VCAM1 gene and risk for symptomatic stroke in sickle cell disease. Blood (2002) 100(13):4303-4309.
40. SEBASTIANI P, RAMONI MF, NOLAN V, BALDWIN CT, STEINBERG MH: Genetic dissection and prognostic modeling of overt stroke in sickle cell anemia. Nat. Genet. (2005) 37(4):435-440.
41. ADAMS R, MCKIE V, NICHOLS F et al.: The use of transcranial ultrasonography to predict stroke in sickle cell disease. N. Engl. J. Med. (1992) 326(9):605-610. This report showed that transcranial ultrasonography provides a non-invasive means for identifying SCD children who are at high risk for stroke.
42. ADAMS RJ, MCKIE VC, CARL EM et al.: Long-term stroke risk in children with sickle ceil disease screened with transcranial Doppler. Ann. Neurol. (1997) 42(5):699-704.
43. SEIBERT JJ, GLASIER CM, KIRBY RS et al.: Transcranial Doppler, MRA, and MRI as a screening examination for cerebrovascular disease in patients with sickle cell anemia: an 8-year study. Pediatr. Radiol. (1998) 28(3):138-142.
44. KUGLER S, ANDERSON B, CROSS D et al.: Abnormal cranial magnetic resonance imaging scans in sickle-cell disease. Neurological correlates and clinical implications. Arch. Neurol. (1993) 50(6):629-635.
45. KIRKHAM FJ, CALAMANTE F, BYNEVELT M et al.: Perfusion magnetic resonance abnormalities in patients with sickle cell disease. Ann. Neurol. (2001) 49(4):477-485.
46. ABBOUD MR, CURE J, GRANGER S et al.: Magnetic resonance angiography in children with sickle cell disease and abnormal transcranial Doppler ultrasonography findings enrolled in the STOP study. Blood (2004) 103(7):2822-2826.
47. SWITZER JA, HESS DC, NICHOLS FT, ADAMS RJ: Pathophysiology and treatment of stroke in sickle-cell disease: present and future. Lancet Neurol. (2006) 5(6):501-512.
48. RUSSELL MO, GOLDBERG HI, HODSON A et al.: Effect of transfusion therapy on arteriographic abnormalities and on recurrence of stroke in sickle cell disease. Blood (1984) 63(1):162-169.
49. PEGELOW CH, ADAMS RJ, MCKIE V et al.: Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J. Pediatr. (1995) 126(6):896-899.
50. ADAMS RJ, MCKIE VC, HSU L et al.: Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N. Engl. J. Med. (1998) 339(1):5-11.
51. ADAMS RJ: Stroke prevention in sickle cell disease. Curr. Opin. Hematol. (2000) 7(2):101-105.
52. ADAMS RJ, BRAMBILLA DJ, GRANGER S et al.: Stroke and conversion to high risk in children screened with transcranial Doppler ultrasound during the STOP study. Blood (2004) 103(10):3689-3694.
53. NICHOLS FT, JONES AM, ADAMS RJ: Stroke prevention in sickle cell disease (STOP) study guidelines for transcranial Doppler testing. J. Neuroimaging (2001) 11(4):354-362.
54. FULLERTON HJ, ADAMS RJ, ZHAO S, JOHNSTON SC: Declining stroke rates in Californian children with sickle cell disease. Blood (2004) 104(2):336-339. Reports the effect of implementing a stroke prevention programme in a regional population.
55. ADAMS RJ, BRAMBILLA D: Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N. Engl. J. Med. (2005) 353(26):2769-2778. A large, multi-centre, randomised investigation to determine whether stopping RBC transfusions was safe in previously screened high-risk patients, showing that long-term transfusion therapy appears necessary to halt strokes.
56. LEE MT, PIOMELLI S, GRANGER S et al.: Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and final results. Blood (2006) 108(3):847-852.
57. PEGELOW CH, WANG W, GRANGER S et al.: Silent infarcts in children with sickle cell anemia and abnormal cerebral artery velocity. Arch. Neurol. (2001) 58(12):2017-2021.
58. KIRKHAM FJ, DEBAUN MR: Stroke in children with sickle cell disease. Curr. Treat. Options Neurol. (2004) 6(5):357-375.
59. STYLES LA, VICHINSKY E: Effects of a long-term transfusion regimen on sickle cell-related illnesses. J. Pediatr. (1994) 125(6Pt 1):909-911.
60. VICHINSKY EP: Current issues with blood transfusions in sickle cell disease. Semin. Hematol. (2001) 38(1 Suppl. 1):14-22.
61. HEDDLE NM, SOUTAR RL, O'HOSKI PL et al.: A prospective study to determine the frequency and clinical significance of alloimmunization post-transfusion. Br. J. Haematol. (1995) 91(4):1000-1005.
62. DAVIES SC, MCWILLIAM AC, HEWITT PE, DEVENISH A, BROZOVIC M: Red cell alloimmunization in sickle cell disease. Br. J. Haematol. (1986) 63(2):241-245.
63. SINGER ST, WU V, MIGNACCA R et al.: Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly asian descent. Blood (2000) 96(10):3369-3373.
64. JACOBS A: Iron overload-clinical and pathologic aspects. Semin. Hematol. (1977) 14(1):89-113.
65. OLIVIERI NF, BRITTENHAM GM: Iron-chelating therapy and the treatment of thalassemia. Blood (1997) 89(3):739-761.
66. VICHINSKY E, BUTENSKY E, FUNG E et al.: Comparison of organ dysfunction in transfused patients with SCD or beta thalassemia. Am. J. Hematol. (2005) 80(1):70-74.
67. HARMATZ P, BUTENSKY E, QUIROLO K et al.: Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood (2000) 96(1):76-79.
68. NISBET-BROWN E, OLIVIERI NF, GIARDINA PJ et al.: Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet (2003) 361(9369):1597-1602.
69. COHEN AR, MARTIN MB, SILBER JH et al.: A modified transfusion program for prevention of stroke in sickle cell disease. Blood (1992) 79(7):1657-1661. Introduction of a modified transfusion regimen that might reduce transfusion exposures and iron loading, yet retain activity in stroke prevention.
70. COHEN A, MARKENSON AL, SCHWARTZ E: Transfusion requirements and splenectomy in thalassemia major. J. Pediatr. (1980) 97(1):100-102.
71. BRADAI M, ABAD MT, PISSARD S et al.: Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia. Blood (2003) 102(4):1529-1530.
72. WARE RE, ZIMMERMAN SA, SCHULTZ WH: Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease. Blood (1999) 94(9):3022-3026.
73. HALSEY C, ROBERTS IA: The role of hydroxyurea in sickle cell disease. Br. J. Haematol. (2003) 120(2):177-186.
74. SUMOZA A, DE BISOTTI R, SUMOZA D, FAIRBANKS V: Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA). Am. J. Hematol. (2002) 71(3):161-165.
75. WARE RE, ZIMMERMAN SA, SYLVESTRE PB et al.: Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. J. Pediatr. (2004) 145(3):346-352. Important clinical trial that demonstrated the possibility that an alternative stroke prevention regimen of HU and phlebotomy might be considered in lieu of chronic RBC transrusions.
76. ZIMMERMAN SA, SCHULTZ WH, DAVIS JS et al.: Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood (2004) 103(6):2039-2045.
77. VICHINSKY EP, LUBIN BH: A cautionary note regarding hydroxyurea in sickle cell disease. Blood (1994) 83(4):1124-1128.
78. HANKINS JS, WARE RE, ROGERS ZR et al.: Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood (2005) 106(7):2269-2275.
79. DE MONTALEMBERT M, BROUSSE V, ELIE C et al.: Long-term hydroxyurea treatment in children with sickle cell disease: tolerance and clinical outcomes. Haematologica (2006) 91(1):125-128.
80. CHAPLIN H JR, ALKJAERSIG N, FLETCHER AP, MICHAEL JM, JOIST JH: Aspirin-dipyridamole prophylaxis of sickle cell disease pain crises. Thromb. Haemost. (1980) 43(3):218-221.
81. ZAGO MA, COSTA FF, ISMAEL SJ, TONE LG, BOTTURA C: Treatment of sickle cell diseases with aspirin. Acta Haematol. (1984) 72(1):61-64.
82. SEMPLE MJ, AL-HASANI SF, KIOY P, SAVIDGE GF: A double-blind trial of ticlopidine in sickle cell disease. Thromb. Haemost. (1984) 51(3):303-306.
83. GREENBERG J, OHENE-FREMPONG K, HALUS J, WAY C, SCHWARTZ E: Trial of low doses of aspirin as prophylaxis in sickle cell disease. J. Pediatr. (1983) 102(5):781-784.
84. SALVAGGIO JE, ARNOLD CA, BANOV CH: Long-term anti-coagulation in sickle-cell disease. A clinical study. N. Engl. J. Med. (1963) 269:182-186.
85. SCHNOG JB, KATER AP, MAC GILLAVRY MR et al.: Low adjusted-dose acenocoumarol therapy in sickle cell disease: a pilot study. Am. J. Hematol. (2001) 68(3):179-183.
86. SCHNOG JB, MAC GILLAVRY MR, ROJER RA et al.: No effect of acenocoumarol therapy on levels of endothelial activation markers in sickle cell disease. Am. J. Hematol. (2002) 71(1):53-55.
87. CHAPLIN H JR, MONROE MC, MALECEK AC et al.: Preliminary trial of minidose heparin prophylaxis for painful sickle cell crises. East Afr. Med. J. (1989) 66(9):574-584.
88. STOCKMAN JA, NIGRO MA, MISHKIN MM, OSKI FA: Occlusion of large cerebral vessels in sickle-cell anemia. N. Engl. J. Med. (1972) 287(17):846-849.
89. POWARS DR: Natural history of sickle cell disease-the first ten years. Semin. Hematol. (1975) 12(3):267-285.
90. BERNAUDIN F, FREARD F, VERLHAC S et al.: In sickle cell disease, overt and silent strokes, low hematocrit and high platelet count, significantly and independently badly influence psychometric performances. Blood (1998) 92:496a.
91. VERMYLEN C, CORNU G, FERSTERA et al.: Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium. Bone Marrow Transplant. (1998) 22(1):1-6.
92. WALTERS MC, PATIENCE M, LEISENRING W et al.: Bone marrow transplantation for sickle cell disease. N. Engl. J. Med. (1996) 335(6):369-376.
93. WALTERS MC, STORB R, PATIENCE M et al.: Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. Blood (2000) 95(6):1918-1924. Update of outcomes after HCT for SCD in a multi-centre trial are summarised. This was the first demonstration of the protective effect of donor haematopoiesis on stroke risk.
94. WALTERS MC, SULLIVAN KM, BERNAUDIN F et al.: Neurologic complications after allogeneic marrow transplantation for sickle cell anemia. Blood (1995) 85(4):879-884.
95. KALINYAK KA, MORRIS C, BALL WS et al.: Bone marrow transplantation in a young child with sickle cell anemia. Am. J. Hematol. (1995) 48(4):256-261.
96. ABBOUD MR, JACKSON SM, BARREDO J et al.: Neurologic complications following bone marrow transplantation for sickle cell disease. Bone Marrow Transplant. (1996) 17(3):405-407.
97. FERSTER A, CHRISTOPHE C, DAN B, DEVALCK C, SARIBAN E: Neurologic complications after bone marrow transplantation for sickle cell anemia. Blood (1995) 86(1):408-409.
98. WOODARD P, HELTON KJ, KHAN RB et al.: Brain parenchymal damage after haematopoietic stem cell transplantation for severe sickle cell disease. Br. J. Haematol. (2005) 129(4):550-552. Single-centre study of a small group of SCD patients after BMT in whom some had evolution of old and new brain parenchymal lesions.
99. WAGNER JE, KERNAN NA, STEINBUCH M, BROXMEYER HE, GLUCKMAN E: Allogeneic sibling umbilical-cord-blood transplantation in children with malignant and non-malignant disease. Lancet (1995) 346:214-219.
100. ROCHA V, WAGNER JE JR, SOBOCINSKl KA et al.: Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N. Engl. J. Med. (2000) 342(25):1846-1854.
101. LOCATELLI F, ROCHA V, REED W et al.: Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. Blood (2003) 101(6):2137-2143.
102. WALTERS MC, QUIROLO L, TRACHTENBERG ET et al.: Sibling donor cord blood transplantation for thalassemia major: experience of the sibling donor cord blood program. Ann. NY Acad. Sci. (2005) 1054:206-213.
103. ADAMKIEWICZ TV, MEHTA PS, BOYER MW et al.: Transplantation of unrelated placental blood cells in children with high-risk sickle cell disease. Bone Marrow Transplant. (2004) 34(5):405-411.
104. LOCATELLI F, GIEBEL S, ARGIOLU F et al.: Unrelated donor bone marrow transplantation for class I-II thalassemia pediatric patients. Blood (2005) 106(11):562a.
105. LA NASA G, GIARDINI C, ARGIOLU F et al.: Unrelated donor bone marrow transplantation for thalassemia: the effect of extended haplotypes. Blood (2002) 99(12):4350-4356.
106. LA NASA G, CAOCCI G, ARGIOLU F et al.: Unrelated donor stem cell transplantation in adult patients with thalassemia. Bone Marrow Transplant. (2005) 36(11):971-975.
107. FLEISCHHAUER K, LOCATELLI F, ZECCA M et al.: Graft rejection after unrelated donor hematopoietic stem cell transplantation for thalassemia is associated with nonpermissive HLA-DPB1 disparity in host-versus-graft direction. Blood (2006) 107(7):2984-2992.
108. NIETERT PJ, ABBOUD MR, SILVERSTEIN MD, JACKSON SM: Bone marrow transplantation versus periodic prophylactic blood transfusion in sickle cell patients at high risk of ischemic stroke: a decision analysis. Blood (2000) 95(10):3057-3064.